A Double Blind, Placebo-controlled First Time in Human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Repeat Doses of GSK3036656 in Healthy Adult Volunteers

Trial Profile

A Double Blind, Placebo-controlled First Time in Human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Repeat Doses of GSK3036656 in Healthy Adult Volunteers

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 08 Aug 2017

At a glance

  • Drugs GSK 3036656 (Primary)
  • Indications Tuberculosis
  • Focus Adverse reactions; First in man; Pharmacokinetics
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 03 Aug 2017 Planned End Date changed from 25 Jul 2017 to 4 Aug 2017.
    • 03 Aug 2017 Planned primary completion date changed from 25 Jul 2017 to 4 Aug 2017.
    • 18 Jul 2017 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top